基因组信息计算生物学平台前瞻性预测AML和MDS治疗反应
研究开发了基于体细胞基因突变和基因拷贝数变异的计算生物学建模与数字药物模拟平台,在前瞻性研究中分析50例可评估MDS和AML患者的基因组数据,盲法预测个体化治疗反应。平台在61次模拟中准确预测55次(90%),灵敏度94%、特异度88%,实验室验证19份样本中17份(89%)蛋白网络预测准确。
要点
- CBM平台在61次模拟中准确预测55次(90%),灵敏度94%、特异度88%。
- TET2、IDH1/2、ASXL1和EZH2基因突变对MDS去甲基化药物反应具有高信息量。
- 实验室验证17/19份(89%)样本中CBM预测的激活蛋白网络准确。
核心结论
- 基于患者癌症基因组学的CBM平台可用于预测MDS和AML患者的精准治疗反应。
研究设计与样本
- 前瞻性试点临床研究(NCT02435550)纳入确诊MDS和AML患者,对50例可评估患者的基因组数据行CBM分析,盲法于实际处方方案预测个体化治疗反应。
主要发现
- CBM在61次模拟中准确预测治疗反应55次(90%),其中真阳性33次、真阴性22次、假阳性3次、假阴性3次。
- 灵敏度94%,特异度88%,准确率90%。
- 实验室验证确认CBM预测的激活蛋白网络在来自11例患者的19份样本中17份(89%)准确。
- 发现TET2、IDH1/2、ASXL1和EZH2基因体细胞突变对MDS去甲基化药物反应具有高度信息量。
临床怎么用
- 利用患者肿瘤基因组信息通过CBM平台模拟药物反应,可辅助预测MDS和AML的精准治疗反应。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) are generally older and have more comorbidities. Therefore, identifying personalized treatment options for each patient early and accurately is essential. To address this, we developed a computational biology modeling (CBM) and digital drug simulation platform that relies on somatic gene mutations and gene CNVs found in malignant cells of individual patients. Drug treatment simulations based on unique patient-specific disease networks were used to generate treatment predictions. To evaluate the accuracy of the genomics-informed computational platform, we conducted a pilot prospective clinical study (NCT02435550) enrolling confirmed MDS and AML patients. Blinded to the empirically prescribed treatment regimen for each patient, genomic data from 50 evaluable patients were analyzed by CBM to predict patient-specific treatment responses. CBM accurately predicted treatment responses in 55 of 61 (90%) simulations, with 33 of 61 true positives, 22 of 61 true negatives, 3 of 61 false positives, and 3 of 61 false negatives, resulting in a sensitivity of 94%, a specificity of 88%, and an accuracy of 90%. Laboratory validation further confirmed the accuracy of CBM-predicted activated protein networks in 17 of 19 (89%) samples from 11 patients. Somatic mutations in the TET2, IDH1/2, ASXL1, and EZH2 genes were discovered to be highly informative of MDS response to hypomethylating agents. In sum, analyses of patient cancer genomics using the CBM platform can be used to predict precision treatment responses in MDS and AML patients.
引用
- Drusbosky LM, Singh NK, Hawkins KE, et al. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients. Blood Adv. 2019. PMID: 31208955. doi:10.1182/bloodadvances.2018028316
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。